Get the Stockscreener App
2.28
16.92%
0.33
After Hours:
2.26
-0.02
-0.88%
Replimune Group Inc stock is traded at $2.28, with a volume of 12.71M.
It is up +16.92% in the last 24 hours and down -68.07% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
See More
Previous Close:
$1.95
Open:
$1.95
24h Volume:
12.71M
Relative Volume:
4.00
Market Cap:
$188.27M
Revenue:
-
Net Income/Loss:
$-314.85M
P/E Ratio:
-0.6364
EPS:
-3.5825
Net Cash Flow:
$-283.27M
1W Performance:
-61.26%
1M Performance:
-68.07%
6M Performance:
-51.90%
1Y Performance:
-70.43%
1-Day Range:
$1.92
$2.30
1-Week Range:
$1.50
$6.65
52-Week Range:
$1.50
$13.24
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
2.28 | 161.02M | 0 | -314.85M | -283.27M | -3.5825 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-03-25 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| Oct-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-20-25 | Upgrade | Wedbush | Neutral → Outperform |
| Sep-19-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Why Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma Application And What's Next - simplywall.st
Mass. biotech company to lay off 63 employees after FDA rejects cancer drug for 2nd time - MassLive
Replimune Group FY2026 EPS Estimate Lifted by HC Wainwright - MarketBeat
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer - BioSpace
Replimune Group, Inc. Cash Ratio | REPL - MLQ.ai
Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma BLA Over Trial Design Concerns - Yahoo Finance
REPL Slides After Insider Filings Spark Trader Caution - StocksToTrade
FDA Rejection Sparks Questions On Replimune Drug Approval Path - Sahm
Replimune plunges after FDA rejects skin cancer drug again - MSN
Jefferies downgrades Replimune Group (REPL) - MSN
Massachussetts Biotech Co. Faces Major Melanoma Drug Setback - Streetwise Reports
Wedbush downgrades Replimune Group (REPL) - MSN
MA Biotech Co. Downgraded to Sell After Second FDA CRL for RP-1 Melanoma BLA - Streetwise Reports
REPL Downgraded by JP Morgan -- Rating Changed to Underweight - GuruFocus
Recon: FDA denies Replimune’s cancer drug over trial issues; Revolution’s cancer pill boosts survival in Phase 3 trial - RAPS.org
Fastenal, Replimune Group, Children's Place and other big stocks moving lower in Monday's pre-market session - MSN
Replimune Plans Layoffs After FDA Rejects Cancer Therapy. The Stock Hits an All-Time Low. - Barron's
REPL Downgraded by Cantor Fitzgerald -- Rating Changed to Neutra - GuruFocus
Replimune plunges after second FDA setback for melanoma therapy; analysts turn bearish - MSN
REPL Downgraded by Wedbush -- Price Target Lowered to $2.00 - GuruFocus
REPL Downgraded by Leerink Partners -- Price Target Lowered to $2.00 - GuruFocus
Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%. -- Barrons.com - Moomoo
REPL Downgraded by Jefferies -- Price Target Lowered to $2.00 - GuruFocus
Replimune Receives FDA Complete Response Letter for RP1 Biologics License Application in Advanced Melanoma, Plans Major Cutbacks - Minichart
Replimune Group (REPL) Faces Downgrades After FDA Rejects Melano - GuruFocus
Replimune Shares Plummet to All-Time Low as FDA Rejection Muddies Path Forward - marketscreener.com
FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment - Pharmaceutical Executive
Replimune Receives Second CRL for RP1 With Nivolumab for Treatment of Advanced Melanoma - Pharmacy Times
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes - Zacks Investment Research
Street sours on Replimune as stock hits all-time low on melanoma drug rejection - Seeking Alpha
Replimune’s RP1 setback deepens after second FDA rejection - The Pharma Letter
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN
Cantor Fitzgerald Reaffirms Neutral Rating for Replimune Group (NASDAQ:REPL) - MarketBeat
Replimune Group REPL Plunges After FDA Melanoma Rejection - StocksToTrade
Biggest stock movers Monday: REPL, GS, LEG and more (NYSE:GS) - Seeking Alpha
Replimune Group (NASDAQ:REPL) Lowered to "Underperform" Rating by BMO Capital Markets - MarketBeat
REPL Downgraded by HC Wainwright & Co. -- Rating Changed to Sell - GuruFocus
Pharmalittle: We're reading about a pancreatic cancer pill, FDA rejecting a Replimune drug again, and more - statnews.com
This NXP Semiconductors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Replimune Group (NASDAQ:REPL) Earns "Market Perform" Rating from Leerink Partners - MarketBeat
Replimune Group (NASDAQ:REPL) Receives "Neutral" Rating from Wedbush - MarketBeat
Replimune Group's (REPL) "Hold" Rating Reiterated at Jefferies Financial Group - MarketBeat
JPMorgan Chase & Co. Reaffirms Underweight Rating for Replimune Group (NASDAQ:REPL) - MarketBeat
FDA issues complete response letter to Replimune’s RP1 for melanoma - Pharmaceutical Technology
Replimune Group (NASDAQ:REPL) Given Sell Rating at HC Wainwright - MarketBeat
Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Sess - Benzinga
US Premarket Movers: Baker Hughes, Goldman, Leggett, Replimune - Bloomberg.com
Replimune Group, Inc. Shareholders Are Encouraged to Reach - GlobeNewswire
Piper Sandler Downgrades Replimune to Neutral From Overweight, Adjusts Price Target to $4 From $14 - marketscreener.com
Replimune melanoma therapy rejected by FDA, shares plunge - Proactive financial news
BMO Capital Downgrades Replimune to Underperform From Market Perform, Adjusts PT to $1 From $11 - marketscreener.com
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):